First treatment for common bladder cancer recommended by NICE
Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration
Read More
Tag: NICE
NICE recommends remote monitoring technology for heart failure patients
Heart failure accounted for approximately 90,000 hospital admissions in England in 2019 to 2020
Read More
NICE recommends Santen’s Roclanda to treat glaucoma and ocular hypertension
Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK
Read More
Theramex’s Eladynos recommended by NICE for post-menopausal bone disease
Osteoporosis currently affects 3.8 million people in the UK, particularly impacting older women after menopause
Read More
NICE nod for Darzalex with lenalidomide and dexamethasone
Therapy has been developed to treat adult patients with newly diagnosed multiple myeloma
Read More
Bristol Myers Squibb’s Camzyos gets NICE recommendation
Therapy is used among adult patients with symptomatic obstructive hypertrophic cardiomyopathy
Read More
Chiesi’s Elfabrio receives NICE recommendation
The therapy has been developed for the treatment of Fabry disease among adult patients
Read More
NICE recommends Amryt’s Filsuvez for rare skin disorder
Around 670 people in England with epidermolysis bullosa will benefit from the treatment
Read More
NICE gives green light for MSD’s Keytruda
The decision is the first verdict based on data from a wider immunotherapy ‘basket’ study
Read More
NICE rejection for CSL Behring gene therapy
Therapy is a treatment option for adults with severe and moderately severe haemophilia B
Read More
BMS’ Sotyktu gets NICE green light for NHS use
The therapy becomes an option for moderate-to-severe plaque psoriasis in certain adults
Read More
NICE nod for AstraZeneca’s Lynparza
Therapy treats patients with specific types of ovarian, fallopian tube or primary peritoneal cancer
Read More
- Acoramidis approved for heart condition treatment
- Genomics study launches to optimise childhood cancer care in Ireland
- UCL researchers launch congenital muscular dystrophy research programme
- Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
- FDA approves Click’s digital therapeutic for episodic migraine
